GlaxoSmithKline (GSK) has signed a definitive agreement to acquire Human Genome Sciences (HGS) for $14.25 per share in cash. The transaction values HGS at approximately $3.6bn on an equity basis, or approximately $3bn net of cash and ...
Tags: GSK, Human Genome Sciences, HGS